Results of an analysis of 2012 cancer incidence and survival from various cancer registries, published in CDC's Morbidity and Mortality Weekly Report, indicates reduced incidence of overall cancer across the United States.
Launched in December 2010, Healthy People 2020 has an agenda to achieve significant improvement in the health of the population in America by 2020, with disease-specific milestones established along the path. The project aims to reduce the number of new cancer cases, illness, disability, and death from cancer.
As a part of this overall objective, CDC analyzes data across the country, comparing cancer incidence and survival rates and reporting them to the public. The latest report has released analysis of data from the U.S. Cancer Statistics (USCS) for 2012, which is the most recent data available. USCS includes high quality incidence data from CDC’s National Program of Cancer Registries (NPCR) and the National Cancer Institute’s Surveillance, Epidemiology, and End Results program (SEER), survival data from NPCR, and mortality data from the National Vital Statistics System.
Here are the key findings of the report:
The authors attribute the decrease in prostate cancer incidence to the recommendation by the US Preventive Service’s Task Force (USPSTF) against using the prostate-specific antigen (PSA) test for screening men for prostate cancer. Studies recorded an 8% reduction in the use of the PSA test following the USPSTF recommendation: from 32% in 2008 to 24% in 2013.
The authors urge the population—and particularly, the healthcare providers—to follow the new screening recommendations by USPSTF for the various cancers to be able to achieve improved cancer outcomes in the population. Maximizing efforts to prevent cancer, improve adherence to cancer screening recommendations, and assure timely and appropriate cancer care for all persons is needed to achieve the national cancer objectives set forth in Healthy People 2020, they write.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More